אפופרוסטנול טבע ® 0.5 מ"ג

Nazione: Israele

Lingua: ebraico

Fonte: Ministry of Health

Principio attivo:

EPOPROSTENOL AS SODIUM 0.5 MG

Commercializzato da:

SALOMON,LEVIN & ELSTEIN LTD

Codice ATC:

B01AC09

Forma farmaceutica:

POWDER AND SOLVENT FOR SOLUTION FOR INFUSION

Via di somministrazione:

I.V

Prodotto da:

TEVA PARENTERAL MEDICINES INC, USA

Gruppo terapeutico:

EPOPROSTENOL

Indicazioni terapeutiche:

Epoprostenol Teva is indicated for the long-term intravenous treatment of primary arterial pulmonary hypertension and arterial pulmonary hypertension associated with the scleroderma spectrum of disease in NYHA class III and class IV patients who do not respond to conventional therapy.

Data dell'autorizzazione:

2009-11-01